Relugolix/estradiol/norethisterone acetate (endometriosis); Benefit assessment according to §35a SGB V; Extract

[ A23-117] Relugolix/estradiol/norethisterone acetate (endometriosis) – Benefit assessment according to §35a Social Code Book V Last updated 01.03.2024 Project no.: A23-117 Commission: Commission awarded on 29.11.2023 by the Federal Joint Committee (G-BA). Report type: Dossier assessment Status: Commission completed Department/Division: Drug Assessment Topic: Reproductive health and birth Symptomatic treatment of adult women of reproductive age with endometriosis who have a history of previous medical or surgical treatment - Women who are eligible for treatment with dienogest: added benefit not proven - Women who are not (or no longer) eligible for treatment with dienogest: added benefit not proven After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website. https://doi.org/10.60584/A23-117_en - Extract of dossier assessment: Relugolix/estradiol/norethisterone acetate (endometriosis) – Benefit assessment according to §35a Social Code Book V DOI: https://doi.org/10.60584/A23-117_en EN, PDF, 345 kB, PDFpublished on Mar 1, 2024 - Dossier assessment: Relugolix/estradiol/norethisterone acetate (endometriosis) – Benefit assessment according to §35a Social Code Book V DOI: https://dx.doi.org/10.60584/A23-117 DE, PDF, 902 kB, PDFpublished on Mar 1, 2024 | Project no. | Title | Status | |---|---|---| | A21-112 | Relugolix/estradiol/norethisterone (uterine fibroid) - Benefit assessment according to §35a Social Code Book V | Commission completed |